OBJECTIVES: To identify possible association between the selected HLA-G gene polymorphisms and risk of pre-eclampsia. BACKGROUND: Pre-eclampsia is a serious multisystem disorder that affects women during pregnancy. Despite many research studies, the pathology of pre-eclampsia is not fully understood. Human leukocyte antigen G (HLA-G) belongs to the molecules that induce fetal acceptance by the maternal immune system. HLA-G expression was found to be impaired in the women suffering from pre-eclampsia suggesting its involvement in the development of pre-eclampsia. METHODS: 123 women with pre-eclampsia and 102 women with normotensive pregnancy were included in the study.
Introduction
Pre-eclampsia (PE) is a serious pregnancy-specifi c disease affecting 2-5 % of pregnancies worldwide. This multisystem disorder is manifested by hypertension (systolic and diastolic blood pressure of ≥ 140/90 mm Hg) and proteinuria (protein excretion of ≥ 300 mg in a 24 hrs urine collection). Advanced clinical symptoms include seizures, renal failure, IUGR (Intrauterine Growth Restriction) and/or HELLP (Hemolysis, Elevated Liver Enzymes and Low Platelets) syndrome. Finally, the generalized damage of the maternal endothelium, kidneys and liver can develop, leading to increased mortality of mother as well as fetus. The clinical symptoms of pre-eclampsia can be observed in the second or the third trimester of pregnancy and are most common in primiparas (1) . Only symptomatic treatment is available to prevent hypertension or convulsive seizures. Radical resolution of pre-eclampsia includes the removal of the placenta and pre-term birth (2) .
Despite many research studies, the pathology of pre-eclampsia is not fully understood. One cause may originate in an insuffi ciently developed placenta, referred to as poor placentation. It is characterized by impaired re-modeling of spiral arteries of the uterus caused by an imbalance of circulating angiogenic factors (3) . Other key mechanisms leading to pre-eclampsia besides poor placentation are infl ammation and aberrant immune interactions at the fetal-maternal interface (4) .
Suitable biomarkers that could predict the risk of PE are still subject of investigation. One of the candidate molecules that plays a benefi cial role in the pregnancy is the human leukocyte antigen G (HLA-G). HLA-G belongs to the non-classical HLA-class I molecules mediating immunosupression. It is mainly expressed in extravillous cytotrophoblasts, which help to protect the fetus from maternal immune response (5) . HLA-G is involved in inhibition of cytotoxic activity of uterine and peripheral blood NK cells and CD8+ T cells, the alloproliferative response of CD4+ T cells, inhibition of dendritic cell maturation and activation of regulatory T cells (6) . Immunosuppressive activity of the HLA-G molecule is mediated mainly through its interaction with inhibitory receptors of immune cells: ILT-2 receptor present on B cells, APC and some T, and NK cells, ILT-4 receptor present on APC and KIR2DL4 expressed by NK and some T cells (6, 7) . In addition to its immunosuppressive activity, HLA-G is involved in ensuring the successful invasion of placental tissues into the maternal decidua (8) .
The HLA-G gene is 4170 bp long and consists of 8 exons. By an alternative splicing of the primary transcript, 7 HLA-G isoforms can be generated. Four isoforms HLA-G1, -G2, -G3 and -G4 are membrane bound, whereas three isoforms HLA-G5, -G6 and -G7 are soluble. Only the structure of HLA-G1 molecule resembles the structure of other full-length HLA-I molecules (9) . HLA-G gene is characterized by low polymorphism, namely 53 HLA-G alleles, 18 HLA-G proteins and 2 null alleles have been identifi ed until now (IMGT/HLA database, January 2017). The most polymorphic sites that infl uence HLA-G expression were identifi ed in the 5′ and 3′ non-coding regions (10, 11) . In the 3′ UTR, the 14 bp insertion polymorphism (5′-ATTTGTTCATGCCT-3′) was described, that affects stability of mRNA causing a lower production of most membrane and soluble isoforms (10) . The HLA-G*01:05N null allele characterized by a single base-pair deletion of cytosine (1597∆C) in exon 3 of HLA-G is associated with an abolished expression of the full-length HLA-G protein isoforms HLA-G1 and HLA-G5 in women who are homozygous for the 1597∆C mutation (12).
The role of HLA-G in pre-eclampsia was determined through observations of a decreased HLA-G expression in mothers suffering from PE (13, 14, 15) . As the expression of soluble HLA-G may be infl uenced by the above-mentioned HLA-G gene polymorphisms, the possible association between these variants and risk of PE was investigated with controversial results. Some studies found a signifi cant increase of the 14 bp insertion polymorphism and the HLA-G 01:05N null allele in women with PE in comparison to women with physiological pregnancies (16, 17, 18) . However, other studies did not confi rm the association of these polymorphisms with PE development (19, 20, 21) . Our study investigated the possible genetic association of selected HLA-G gene polymorphisms and the risk of pre-eclampsia in Slovak pregnant women.
Materials and methods

Study subjects
We investigated 123 women suffering from pre-eclampsia and 102 women with physiological pregnancies. PE was defi ned as the presence of blood pressure of at least 140/90 mmHg with readings at least 6 hrs apart and proteinuria (300 mg/24 h or ≥ 30 mg/dl by urine analysis (22) . The clinical characteristics of the women with PE are shown in the Table 1. The mean age of women with PE was 32 ± 5.07 years; the mean age of controls was 36.32 ± 5.08. All study subjects provided a written informed consent for enrolling in the study and for personal data management. The study was approved by the Ethics Committee of the University Hospital Bratislava. All the investigations were carried out in accordance with the International Ethical Guidelines and the Declaration of Helsinki.
Genotyping of HLA-G gene polymorphisms
Both patient and control DNA was extracted from EDTA-treated peripheral blood samples by a modifi ed salting out procedure (23) . To quantify the amount and purity of DNA, the Nanodrop spectrophotometer was used (Thermo Fisher Scientifi c). Two HLA-G gene polymorphisms were studied: the 14 bp insertion/ deletion polymorphism in the 3' UTR (rs66554220) and the cytosine deletion at codon 130 in exon 3 (1597∆C, rs41557518) tagging HLA-G*01:05N null allele. Genotyping of HLA-G 14-bp insertion/deletion polymorphism was performed as described by Hviid et al (24) . Briefl y, DNA was amplifi ed by forward primer 5′GTGATGGGCTGTTTAAAGTGTCACC-3′ and reverse primer 5′GGAAGGAATGCAGTTCAGCATGA-3′ using a PCR cycler (Biometra). Reaction mixture with a total volume of 25 μl contained 50 ng of template DNA, 0.2 mM of each dNTP (Thermo Fisher Scientifi c), 1 unit of Taq DNA polymerase (Thermo Fisher Scientifi c), 1.5 mmol MgCl 2 (Thermo Fisher Scientifi c) and 10 pmol of each specifi c primer. PCR conditions were 95 °C for 3 min, followed by 30 cycles (denaturation at 95 °C for 1 min, annealing at 64 °C for 1 min and elongation at 72 °C for 1 min) and fi nal elongation at 72 °C for 10 min. The PCR products were run in 3 % agarose gel for 20 min. and then visualized under UV-light. Fragment size was confi rmed using the 100 bp DNA ladder (SBS). PCR fragments of 224 bp (14 bp insertion) and PCR fragments of 210 bp (14 bp deletion) were identifi ed ( Fig. 1) . The presence of the HLA-G*01:05N null allele was performed by PCR-RFLP as described by Alizadeh et al (25) . Genomic DNA was amplifi ed by forward primer 5'CAGGTTCTCACACCCTCCAG3' and reverse primer 5'CCTCCACTCCCTCAGAGACTTCATC3'. PCR conditions were the same as by HLA-G 14 bp genotyping except for the annealing at 63 °C for 30 sec. Amplifi cation of PCR products of 504 bp was confi rmed in 1.5 % agarose gel. PCR products were digested with FastDigest pPPUMI restriction enzyme at 37 °C for 3 hrs, according to manufacturer's instructions (Thermo Fisher Scientifi c). The restriction products were run in 2 % agarose gel for 20 min, either producing an intact PCR fragment (presence of the HLA-G*01:05N allele) or two fragments of 389 bp and 115 bp (absence of the HLA-G*01:05N allele) (Fig. 2) .
Statistical analysis
Allele and genotype frequencies were calculated by a direct counting. The data were tested for the Hardy-Weinberg equilibrium. The statistical analysis was performed by chi-square test using SNPstats web software available at http.//bioinfo.iconcologia. net/snpstats/start.htm. The odds ratios (OR) and 95 % confi dence intervals (95% CI) were calculated in co-dominant, dominant and recessive inheritance models. Multivariate logistic-regression analysis adjusted for age as a possible infl uencing factor was also performed. Linear regression analysis was used to investigate the correlation between observed HLA-G genotypes and the main clinical features as the onset of PE, the highest systolic blood pressure (BP), the highest diastolic BP, serum creatinine, uric acid and total serum proteins level. The p < 0.05 was considered as statistically signifi cant.
Results
Characteristics of the women with pre-eclampsia
The clinical characteristics of the women with PE are shown in the Table 1 . The mean age of women with PE was 32 ± 5.07 years. Out of 123 women with PE, 75 were primiparous. Early disease onset (before 37 th week of gestation) was developed in 47 women. The mean gestation week at PE onset was 34.76 ± 4.29.
Regarding the disease severity, mild PE (BP ≤ 140/90 mmHg) was classifi ed in 27 women, moderate PE (BP from 140/90 to 150/100 mmHg) was classifi ed in 59 women and severe PE (BP ≥ 160/110 mmHg) was observed in 37 women. The mean highest systolic blood pressure of the women with PE was 154.36 ± 16.01 mmHg, the mean highest diastolic blood pressure was 98.99 ± 9.63 mmHg. Oedemas were observed in 96 women suffering from PE.
HLA-G allele and genotypes frequencies in women with PE and controls
Genotyping was used to determine HLA-G 14 bp insertion/deletion polymorphism and HLA-G 1597∆C polymorphism tagging the HLA-G*01:05N null allele in two studied groups: women with PE (n = 123) and controls (n = 102). Allele and genotype frequencies of HLA-G gene polymorphisms are shown in Tables 2 and  3 
Tab. 2. HLA-G 14 bp allele and genotypes frequencies in women with PE and control group.
tagging the HLA-G*01:05N null allele showed no differences between the PE cases and controls as well (Tab. 3). In the group with PE, 14.63 % of women carried one copy of the 1597∆C allele vs 10.78 % of normotensive women (p = 0.34, OR = 1.42, 95% CI = 0.64-3.16). Women carrying two copies of the 1597∆C allele were not identifi ed in any group. Multivariate logistic-regression analysis adjusted for age showed slightly decreased p values for both HLA-G gene polymorphisms in comparison with univariate analysis, however no statistically signifi cant difference was found. The effect of HLA-G genotypes on clinical fi ndings like the onset of PE, the highest systolic BP, the highest diastolic BP, level of serum creatinine, uric acid and total serum proteins level have been analyzed as well. As given in Tables 4 and 5 , comparison of investigated clinical fi ndings with HLA-G genotypes did not reveal any signifi cant differences (p > 0.05).
Discussion
Pre-eclampsia is one of very serious complications during pregnancy. Despite treatment, this multisystem disorder still remains a major cause of maternal and neonatal mortality and morbidity worldwide. Several promising markers identifying the risk of PE have been described; however, no screening test is available up to date. According to clinical data, the potential biomarkers of PE should be connected with pathophysiology of the angiogenesis and infl ammation (26) . Immunosuppressive molecule HLA-G belongs to candidate molecules with the potential to predict PE diagnosis. An important role of HLA-G in fetal development was described more than 20 years ago (5). The molecule is mainly expressed on trophoblast cells in the placenta and induces the immune tolerance of fetus by maternal immune response (5, 6) . In relation to pregnancy disorders, an association between HLA-G polymorphism, HLA-G level and HLA-G function was described (6) . However, there is no consensus, which HLA-G variants predispose to complications of pregnancy, such as recurrent miscarriages or pre-eclampsia.
In our study, we have analyzed two HLA-G gene polymorphisms affecting its expression: HLA-G 14 bp insertion/deletion polymorphism in the 3ʹ UTR and HLA-G 1597∆C polymorphism tagging HLA-G*01:05N null allele. The 14-bp ins/del (rs 66554220) polymorphism in the 3′ UTR is the most studied HLA-G gene polymorphism. This polymor- phism has been shown to infl uence HLA-G mRNA transcript size and stability (10) . The 14 bp insertion polymorphism has been associated with lower levels of soluble HLA-G suggesting its role in PE development (13, 27) . We did not fi nd any statistically signifi cant differences in HLA-G 14 bp ins/del allele and genotype distribution between women with PE and controls as given by others (19, 20, 28, 29) . The newest meta-analysis of several smaller studies also revealed no associations between the HLA-G 14 bp ins/del genotype and development of PE (30) . However, some studies found a signifi cant increase of the +14/+14 genotype in women with PE in comparison to women with physiological pregnancies (16, 17) . Within HLA-G gene polymorphisms, two null alleles, HLA-G*01:03N and HLA-G*01:05N, have been described. The HLA-G*01:05N null allele is characterized by a single base pair deletion cytosine in exon 3 (1597∆C), which inhibits production of the full-length HLA-G protein isoform HLA-G1 and soluble HLA-G5. However, this null allele retains its ability to translate membrane -bound HLA-G2 and HLA-G3 and soluble HLA-G6 and HLA-G7 isoforms (12). Our study did not reveal any association of heterozygotes carrying HLA-G*01:05N null allele with an increased risk of PE as given by others (21) . This fi nding suggests that heterozygotes could compensate the lack of full length HLA-G1 isoform that contributes to proper invasion of maternal spiral arteries by extravillous cytotrophoblast. Our observations did not confi rm the results published by Loisel et al (18) , who found a signifi cantly increased frequency of the maternal 1597∆C allele in African-American women with PE compared to normal pregnancies (p = 0.00027). Controversial results could be explained by different HLA-G*01:05N null allele distributions in various ethnic populations. The HLA-G*01:05N allele is relatively frequent allele in African-Americans (7.4 to 8 %). The lower frequency was found in Middle Europeans (2.3 %) and Northern Europeans (0.6 %) (31, 32, 33) . Above all, the frequency of HLA-G*01:05N allele was the highest in Iranian populations (20 %) (34) . Our study found out that in healthy Slovak women the frequency of HLA-G*01:05N null allele was 5.39 %, in Slovak women with PE the frequency of HLA-G*01:05N null allele has increased to 7.32 %. Homozygous women carrying the HLA-G*01:05N null allele were not found in our study.
Many studies have shown that the HLA-G level was associated with complications of pregnancy like recurrent miscarriages and preeclampsia (14, 15, 29, 35, 36, 37) . Our results did not reveal any association between the HLA-G 14 bp polymorphism and the 1597∆C polymorphism tagging the HLA-G*01:05N null allele and the risk of pre-eclampsia in Slovak women. However, other HLA-G polymorphisms affecting its expression should also be investigated in order to determine the risk factor for PE. The polymorphisms in the 3′UTR that can infl uence soluble HLA-G level include SNPs at the +3142 position (C/G), at the +3187 (A/G) and +3196 (C/G). The +3142 polymorphism is a target for certain miRNAs that are responsible for degrading HLA-G mRNA. Furthermore, the +3187 and the +3196 SNPs are located just before and after an AUUUA motif associated with mRNA stability (11) .
